The Phase 2 AURELIO-04 study is expected to enroll up to 300 patients across six different indications The study will be conducted in the US and selected European countries and will begin in the first half of 2022 BASEL, Switzerland – SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group,...
treatment News
PRAGUE, BASEL, Switzerland & BOSTON, Mass. — SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced favorable preclinical results supporting the development of SOT106, its antibody-drug conjugate for the treatment of sarcoma, at the Connective Tissue Oncology Society (CTOS) Annual Meeting taking place November 12-15, 2025, in...
SEATTLE, Washington — Sound Pharmaceuticals (SPI) is pleased to announce that the FDA has granted its investigational new drug, SPI-1005, Breakthrough Therapy Designation (BTD) for the treatment of hearing loss in patients with Meniere’s disease (MD). MD is a complex inner ear disease that involves low-to-mid frequency hearing loss, tinnitus,...
L’Hospitalet de Llobregat, Spain – Once they enter the body, drugs, apart from carrying out their therapeutic function, are biochemically transformed by the action of the metabolic machinery, a process that facilitates their expulsion. This biotransformation results in a gradual disappearance of the drug, which is converted into its metabolites....
Paris, France – SparingVision, a clinical-stage genomic medicine company transforming the treatment of retinal disease, today announces a key advancement in its Phase I/II clinical trial (PRODYGY, NCT05748873) for SPVN06, the Company’s lead gene-agnostic investigational gene therapy for the treatment of retinitis pigmentosa (RP). The trial has now progressed to...
HENDERSON, Nev. – Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced the presentation of safety and efficacy results from Cohort 4 of the ZENITH20 clinical trial. This data is from 48 first-line patients with non-small cell lung cancer (NSCLC) with HER2 exon...
Urbana, IL – The Speech Accessibility Project has expanded its recruitment and is inviting U.S. and Puerto Rican adults living with amyotrophic lateral sclerosis to participate. Those interested in participating can sign up online. Funded by Big Tech companies Amazon, Apple, Google, Meta, and Microsoft, the University of Illinois Urbana-Champaign aims...
FDA Authorizes Expanded Access Program (EAP) to Help Provide Access to SPG302 for 200 ALS Individuals Ineligible for Clinical Study EAP Supports Real-world Data Collection Concurrent to Ongoing Clinical Studies of SPG302 LOS ANGELES, Calif. — Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to...
BARCELONA, Spain — SpliceBio, a clinical-stage genetic medicines company pioneering protein splicing to address diseases caused by mutations in large genes, today announced that the first patient has been dosed in the Part B dose-expansion portion of the Phase 1/2 ASTRA clinical trial of SB-007, a dual adeno-associated viral (AAV)...
JERUSALEM, Israel — SpliSense, a clinical-stage biotechnology company developing transformative RNA-based therapies for pulmonary diseases, today announced that the European Medicines Agency (EMA) has granted early Priority Medicines (e-PRIME) designation to SPL84 for the treatment of cystic fibrosis (CF) in patients carrying the 3849+10Kb C>T mutation in the CFTR gene. The e-PRIME designation...